Mycobacterium tuberculosis Beijing type mutation frequency--author's response

Comment

Jurriaan E M de Steenwinkel et al. Emerg Infect Dis. 2013 Mar.

. 2013 Mar;19(3):522-3.

doi: 10.3201/eid1903.121849.

No abstract available

Comment on

Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB.
de Steenwinkel JE, ten Kate MT, de Knegt GJ, Kremer K, Aarnoutse RE, Boeree MJ, Verbrugh HA, van Soolingen D, Bakker-Woudenberg IA. de Steenwinkel JE, et al. Emerg Infect Dis. 2012 Apr;18(4):660-3. doi: 10.3201/eid1804.110912. Emerg Infect Dis. 2012. PMID: 22469099 Free PMC article.

1. Werngren J. Mycobacterium tuberculosis Beijing type mutation frequency [letter]. 10.3201/eid1903.121001 - DOI - PMC - PubMed
1. Werngren J, Hoffner SE. Drug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rate. J Clin Microbiol. 2003;41:1520–4. 10.1128/JCM.41.4.1520-1524.2003 - DOI - PMC - PubMed
1. Bergval IL, Schuitema AR, Klatser PR, Anthony RM. Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance. J Antimicrob Chemother. 2009;64:515–23. 10.1093/jac/dkp237 - DOI - PMC - PubMed
1. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. Approved standard M24–A2. 2nd ed. Wayne (PA): The Institute; 2011. - PubMed